Discussion: In vitro, V118 is reported to confer resistance to 3TC and other nucleoside analogues only in combination with other mutations like D67N and T215Y.
Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.
PMID: 21927716
2011
Journal of AIDS & clinical research
Discussion: Among eight patients with TAMs, the most common pathway (seen in 6/8 patients) was TAM-2 related (D67N, K70R, K219Q/R/E); and the rest (2/8) were mixed with the TAM-1 pathway (M41L, L210W, T215Y) extending similar prior Southern African observations.
A structural frame for understanding the role of thymidine analogue resistance mutations in resistance to zidovudine and other nucleoside analogues.
Introduction: With regard to subtype, in subjects infected with HIV-1 subtype B, the thymidine analogue mutations pathway 1 or TAM-1 (including mutations M41L, Result: Longer duration of virologic failure was found significantly associated with higher risk of all TAM-2 mutations (D67N, K70R, K219Q/E, T215F) and the T215Y mutation with ORs ranging from 1.25 to 1.84 and PP[OR>1]>98% (Figure 2D).
Result: The cluster D67N-K70R-K219Q-M184V, the first three of which are in the TAM-2 pathway, contained the NRTI mutations most likely to occur together in both treatment groups (Figure 3B).
Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006.
Abstract: Genotypic drug resistance analysis showed significant increases in percentages of patients carrying HIV-1 strains with M41L, T215Y/F, D67N, K103N, G190A/S, Y181C/F or L210W mutations.
Correlation between resistance profile and immunosuppression in heavily treated HIV-1 infected Romanian patients.
PMID: 22180722
2011
Romanian biotechnological letters
Result: Thymidine analog mutations, TAMs, selected by zidovudine (AZT) and stavudine (D4T) were usually accompanying this mutation; TAM-2 pathway (mutations D67N, K70R, T215F) was most commonly encountered in immunossupressed patients (28.6%), as well as other substitutions that by themselves, or while accompanying other mutations, confer NRTI resistance: K219E/K/Q (38.1%) and T69N (19%).
Does GSS still maintain relevance on HAART outcome after the introduction of newest active antiretroviral drugs? 48 weeks results.
Result: Mutations associated with resistance to nucleoside analogues (NAMs) were also more frequent among women exposed only to dual-drug PLAT (M41L, 5.0%; D67N, 5.0%; K70R, 10.0; and T215Y, 5.0%) than in those treated with 3 drugs (M41L, 1.1%; D67N, 1.1%; K70R, 1.1%; L210F, 1.1%; K219Q, 1.1%).
Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali.
PMID: 19933171
2010
The Journal of antimicrobial chemotherapy
Abstract: Among the children with detectable VL, 30/37 genotypic resistance tests were available, 8 with wild-type viruses and 22 with resistance mutations (73%): 19 M184V/I, 21 NNRTI mutations and only 3 thymidine analogue mutations (TAMs) (K70R, D67N and L210W in three distinct viruses).
Low-abundance HIV species and their impact on mutational profiles in patients with virological failure on once-daily abacavir/lamivudine/zidovudine and tenofovir.
PMID: 20008905
2010
The Journal of antimicrobial chemotherapy
Introduction: M41L, D67N, K70R, L210W, T215F/Y and K219Q/E), such that they are rarely detected in vivo in the same sample by population sequencing.
Result: At baseline, Subject 5 had viral clones containing K103N with or without T215A, or with Y188L resistance mutations, while at VF clones with one or more of the following mutations: M41L, D67N, K70R, M184V, Y188L, T215F or L, and K219E were detected, but
HIV mutation literature information.
PMID: 
2011
PloS one
Browser Board
Co-occurred Entities
Filtrator
ViMRT